PCM
ALXN

Palisade Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Palisade Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,700
Closed -$206K – 452
2017
Q1 		$206K Sell
1,700
-1,300
-43% -$168K 0.01% 416
2016
Q4 		$367K Buy
+3,000
New +$367K 0.01% 424
2015
Q2 		– Sell
-2,201
Closed -$381K – 546
2015
Q1 		$381K Hold
2,201
– – 0.01% 466
2014
Q4 		$407K Sell
2,201
-650
-23% -$120K 0.01% 439
2014
Q3 		$473K Sell
2,851
-1,261
-31% -$207K 0.01% 431
2014
Q2 		$642K Sell
4,112
-768
-16% -$121K 0.02% 401
2014
Q1 		$742K Sell
4,880
-2,449
-33% -$389K 0.02% 381
2013
Q4 		$974K Sell
7,329
-2,534
-26% -$304K 0.03% 339
2013
Q3 		$1.15M Sell
9,863
-9,697
-50% -$1.06M 0.03% 341
2013
Q2 		$1.8M Buy
+19,560
New +$1.88M 0.05% 322

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $431B AUM 30.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return